Price Alert

Revance Therapeutics Inc. (RVNC)

NASDAQ: RVNC · Real-Time Price · USD

3.65

0.00 (0.00%)

At close: Feb 05, 2025, 3:59 PM

Revance Therapeutics Statistics

Share Statistics

Revance Therapeutics has 104.39M shares outstanding. The number of shares has increased by 0.2% in one year.

Shares Outstanding	104.39M
Shares Change (YoY)	0.2%
Shares Change (QoQ)	0%
Owned by Institutions (%)	78.6%
Shares Floating	91.29M
Failed to Deliver (FTD) Shares	1,844,650
FTD / Avg. Volume	62.35%

Short Selling Information

The latest short interest is 3.84M, so 3.68% of the outstanding shares have been sold short.

Short Interest	3.84M
Short % of Shares Out	3.68%
Short % of Float	4.23%
Short Ratio (days to cover)	1.13

Valuation Ratios

The PE ratio is -2.3 and the forward PE ratio is -16.59. Revance Therapeutics's PEG ratio is 0.11.

PE Ratio	-2.3
Forward PE	-16.59
PS Ratio	3.18
Forward PS	1
PB Ratio	-4.91
P/FCF Ratio	-3.33
PEG Ratio	0.11

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Revance Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.8, with a Debt / Equity ratio of -3.16.

Current Ratio	3.8
Quick Ratio	3.29
Debt / Equity	-3.16
Debt / EBITDA	-1.65
Debt / FCF	-2.14
Interest Coverage	-16.37

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$392.03K
Profits Per Employee	$-542.69K
Employee Count	597
Asset Turnover	0.49
Inventory Turnover	3.34

Taxes

Income Tax	300K
Effective Tax Rate	-0.09%

Stock Price Statistics

The stock price has increased by -44.7% in the last 52 weeks. The beta is 0.95, so Revance Therapeutics's price volatility has been higher than the market average.

Beta	0.95
52-Week Price Change	-44.7%
50-Day Moving Average	3.43
200-Day Moving Average	4.16
Relative Strength Index (RSI)	59.53
Average Volume (20 Days)	2,958,312

Income Statement

In the last 12 months, Revance Therapeutics had revenue of 234.04M and earned -323.99M in profits. Earnings per share was -3.83.

Revenue	234.04M
Gross Profit	81.88M
Operating Income	-316.78M
Net Income	-323.99M
EBITDA	-290.64M
EBIT	-304.33M
Earnings Per Share (EPS)	-3.83

Full Income Statement

Balance Sheet

The company has 137.33M in cash and 478.43M in debt, giving a net cash position of -341.11M.

Cash & Cash Equivalents	137.33M
Total Debt	478.43M
Net Cash	-341.11M
Retained Earnings	-2.08B
Total Assets	461.56M
Working Capital	249.64M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -216.57M and capital expenditures -6.89M, giving a free cash flow of -223.46M.

Operating Cash Flow	-216.57M
Capital Expenditures	-6.89M
Free Cash Flow	-223.46M
FCF Per Share	-2.64

Full Cash Flow Statement

Margins

Gross margin is 34.98%, with operating and profit margins of -135.35% and -138.43%.

Gross Margin	34.98%
Operating Margin	-135.35%
Pretax Margin	-138.3%
Profit Margin	-138.43%
EBITDA Margin	-124.18%
EBIT Margin	-135.35%
FCF Margin	-95.48%

Dividends & Yields

RVNC does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for RVNC is $3.1, which is -15.1% lower than the current price. The consensus rating is "Hold".

Price Target	$3.1
Price Target Difference	-15.1%
Analyst Consensus	Hold
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-6.26
Piotroski F-Score	3